Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm curious about Intracoastal Capital's beneficial ownership statement filed for Baudax, in the week before Dale sold his Baudax shares, which was one day ahead of the Baudax delisting. Will this somehow translate into a gateway for Humanigen to acquire an interest in Tera-Immune through Intracoastal Capital?
https://www.sec.gov/cgi-bin/browse-edgar?company=baudax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I just think that Humanigen has a real interest in Tera-Immune's novel Treg-based cell therapies for autoimmune diseases.
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
The timing is worth noting. If there is a connection between these transactions, maybe we'll find out on or before Monday, when the market is closed. It wouldn't be the first time the company announced major news on a day when the market is closed.
Welcome to the room, LuckyWanderer21.
I saw shares trade for over $200 per share during the first recall of the company's loaned shares. Of course, price wasn't sustained at that level. Prices dropped as the brokerages bought-in their clients who were short. This was in the November/December 2015 time frame. The chart linked below doesn't quite reflect share prices that high, but I think that's because the chart doesn't reflect data from all of the worldwide exchanges. The highest price I see during the referenced time frame was just over $174.
https://www.google.com/search?q=kalobios+stock+price+history&oq=kalobios+stock+price+history&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigAdIBCjE4Njg1ajBqMTWoAgCwAgA&sourceid=chrome&ie=UTF-8
But I know what prices I saw, up to about $248, as I recall. And those prices were initially charted.
Of course it seems far-fetched. But, in my opinion, the company has been steadily loaning shares in preparation of a second recall of their loaned shares, which I eagerly await.
But, if you have reason to think management has no plan for individual shareholders, please enlighten us. On second thought, don't bother.
Welcome to the room, lakers17. Could prove to be perfect timing.
Good move!
My only chance at making real money is if we have a successful short squeeze during the recall of our loaned shares, and I am fortunate at getting filled on my sell orders. I may just bite the tax bullet so that my daughters won't have to worry about that. But I don't know yet what I'll do.
Yes, I think you have several accounts you manage for your family, with $50 sell prices. I hope the bid gets run up, and those orders fill, maybe with a premium price.
Um...I didn't hear you. Can you say it again?
I've been curious about how management would time the upcoming events. Specifically, I wondered if management would begin to roll-out our immediate course change before or after the bankruptcy was concluded. Now we know.
Some years ago, I was disappointed that a number of prospective investors were denied purchases of shares because we were over-subscribed. I had hoped that management would accommodate them, which they did not do. But that was the right business decision at that time, just as concluding the bankruptcy before announcing new developments is the right business decision at this time.
I'm truly not concerned in the least bit. If short sellers were students of what this management team has done by capitalizing on the design of their share structure, they would have saved themselves the pending circumstance of being forced to buy-in their borrowed shares by submitting a bid to the bankruptcy judge. Now, however, I will be happy to provide shares at $200 for them to cover their short positions.
If Big Pharma deduced that Humanigen has created partnerships with Novavax and Gracell, and that we have a pathway to regulatory approval, even if initially overseas, they, too, would have submitted bids for the company. But Gilead's Daniel O'Day, and others, couldn't quite envision that, and will lose substantial market share in the near term, as a consequence.
I think our success is more of a sure shot, than a long shot. I think management anticipated events to unfold as they have, and they planned accordingly and brilliantly. All the pieces are coming together, and I hope that the results of management's efforts will prove life-changing for shareholders, and life-saving for future patients. I'm not surprised or worried about any of the developments we are seeing.
Investors are really sweet on Gracell, as we see a third Beneficial Ownership filing for them on Feb 14th, this one, "...subject to a Beneficial Ownership Blocker (as defined below)," which limited the acquisition to a total 9.99% stake in the company.
https://www.sec.gov/Archives/edgar/data/1346824/000110465924023999/tm246065d12_sc13ga.htm
Are these investors reacting to Gilead/Kite's announcement two weeks ago of FDA approval to "speed up" their CAR-T turnaround time from 16 days to 14 days?
https://www.fiercepharma.com/manufacturing/gileads-kite-wins-fda-nod-new-car-t-manufacturing-process-speed-yescarta-turnaround
This compares to Gracell's recently enhanced (with lenz?) "...FasT CAR solution, preparation time can be cut to 24 hours, significantly reducing production cost and waiting time."
https://www.pharmasources.com/industryinsights/54541.html
It appears that Dale may have dumped his Baudax shares. I'll continue monitoring the Baudax filings, in case we see Tera-Immune news.
https://www.sec.gov/Archives/edgar/data/1178179/000101359424000171/baudax13ga1-02142024.htm
I hate speaking about ethnicities, especially when my natural-born daughters are Amer-Asian. But we know one illegal Chinese-owned biolab has already been discovered operating in California. And I admit that I am concerned about this influx of illegal immigrants, and their objectives in coming here. I think it is in our national security interest to have lenz approved as a vaccine adjuvant, as well as a respiratory tract therapeutic.
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
I'm not surprised by your comment. You have generally been more skeptical than I have been. But who hasn't been? It's been a tough road for shareholders.
But, it really is hard to comprehend the scope of our pending success. I understand that. It will be unparalleled. I've got faith in management, and in lenz. Even Ifab looks promising.
I just don't see a departure from the path management has been on since the company was established. I remain very optimistic and excited.
Maybe I missed somethings that you are aware of. Please show me, for example, why management has an obligation to discuss developments regarding Novavax.
I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax. That list was developed over the years for reasons I disclosed, as I thought each company represented an opportunity for Humanigen.
But those are my opinions. They do not place an obligation on management to comment. I am not a spokesman for the company. At best, I express what I think management may be doing, and I think they WILL comment on each of those companies as our transition continues.
Gracell sees a second amended 13G filed yesterday.
https://www.sec.gov/Archives/edgar/data/1826492/000121390024013387/ea193538-13ga1vivo_gracell.htm
Of course, the biggest bang for Durrant's drug development program dollars, isn't even mentioned in my earlier post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173802006
I have assumed that Novavax has been evaluating the use of lenz with their covid vaccine. Durrant may intend on integrating lenz with an anti-viral and polyclonal antibodies, in a fully developed cocktail, in accordance with our patent. A good amount of investment dollars seem to be flowing into Novavax now. How exciting!!
Two more amended 13G's filed today. One each for Gracell and Novavax.
https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
https://www.sec.gov/Archives/edgar/data/102909/000110465924021584/tv01573-novavaxinc.htm
Durrant appears open to future discussions with unsecured creditors at a time and place TBD. I'm not worried about it way way or the other.
Recalling the loaned shares would force the buy-in of those borrowed shares. Additional shares can't be offered without diluting shareholders. I think our float is 229M shares, which is 192% of our OS.
My ultimate hope, financially, is that management executes the recall of their loaned shares. It's exciting to see all the steps they are now taking, one after the other, to make this happen. I really don't see how the recall could be thwarted at this point.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173806573
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173782405
I think the recall of our loaned shares could be executed now.
But I don't think it will be. I think the recall will come with news that Humanigen could own between 89-92% of all Outstanding Shares. That degree of control has been long established.
And then, we get to new developments, potentially in regards to regulatory approval for CMML, with a possible PRV. Or news about partnerships, such as with Novavax, perhaps with an Advanced Purchase Agreement for the lenz/vaccine compound, and details about our Tera-Immune acquisition, or detail about a licensing agreement with Gracell. There's so much explosive potential! I'm looking forward to seeing it all!
In your fortunate situation, your opinion is easy to understand.
Who are the people in our neighborhood? We've seen recent beneficial ownership documents filed for both Baudax and Gracell. I can't wait to see how this helps Humanigen leverage our position with Tera-Immune and with CAR-T enhancement. We've got documented evidence of our interest in both companies.
But I'm most excited to see how a relationship may develop between Humanigen and Novavax, even though I have seen no evidence to believe that a specific relationship is being developed. I base my suspicion on our patented lenz/vaccine cocktail, and on what I perceive as unmet needs that the two companies can provide for each other. I'm super-excited at the prospect of a partnership being announced. And we have seen several beneficial ownership documents filed recently for Novavax, as well.
D***,
"D ⭐️⭐️⭐️
@_flyers77
What are the different options of how this can play out?"
What are the different options of how this can play out?
— D (@_flyers77) February 11, 2024
"February 12, 2024 at 4:00 p.m. (Eastern): Deadline to submit Bid to be considered for the Auction.
February 13, 2024 at 4:00 p.m.: Sale Objection Deadline
February 13, 2024 at 10:00 a.m.: Auction (if necessary)
see pg 10/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1056710&projectCode=HUM&docketNumber=64&source=DM
Tomorrow could be a pivotal day for us. I hope things go as I expect, and that we may see additional news, as well. I think management has executed superbly.
Morgan Stanley today announced the acquisition of 7,281,646 shares of Novavax (6.2% stake).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Third beneficial ownership filing in about 5 weeks (State Street/SSGA and Blackrock).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Novavax has almost the same OS that Humanigen has, (Shares Outstanding 118.79M) and they are now trading at a 52 week low. I would love to see a stock-for-stock business combination or partnership with them. Huge potential. Look at their 5 year chart.
https://ih.advfn.com/stock-market/NASDAQ/novavax-NVAX/chart/real-time
Even if they only used the lenz vaccine cocktail for immuno-compromised and elderly patients, and even if that only popped our Market Cap to $8B, that could still be a sustained annual revenue of $67 per share for Humanigen.
Yes, I have a recognized, long-standing, pro-bias opinion toward Novavax. But we developed our patent for a reason, and this is the ideal application for that patent.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL
https://patents.justia.com/assignee/humanigen-inc
I think the float of 192% of our OS came from our Transfer Agent to the Nasdaq Appeals Hearing committee, at their request. And yes, those shares will have to be bought-in during the recall of our loaned shares. I think Humanigen controls 110M of the 119M shares in our OS (92% of the shares controlled by the company, versus 70% of the shares the company owned in the previous recall of our loaned shares). This is my opinion along with why I came to this conclusion.
I go back to the reported float of 229M shares, which is >192% of our OS, and which I think Humanigen has control of 110M of those shares.
The only thing I want more than that is the recall of our loaned shares. But I want both the recall and the relisting as the profitable company we are about to become.
I think we are about to blaze new frontiers of safety and efficacy across treatments of multiple indications. CMML is probably the nearest horizon, and it has not only the prospect of an expedited regulatory approval, but also the promise of a Priority Review Voucher. And of course, the biggest impact could be in using lenz as both a covid therapeutic as well as with the Novavax vaccine. And I'm very curious to see if Durrant pursues using Ifab as an ADC for Glioblastoma before CytoDyn gets too far into their program for this indication. Also, Kite/Gilead continues to be a joke, with Gilead's magrolimab failure, and Kite touting a reduction in processing time from16 days, down to 14 days, for their CAR-T, which compares to 24 hours for Gracell's new processing time. And the Class Action lawyers faulted Humanigen for not recognizing magrolimab as a viable competitive product. Gilead abandoned their magrolimab trial for lack of efficacy. That's why I told eb that I was sick and tired of looking at the Class Action suit. Lead Counsel did more to harm shareholders than the $0.047 they have settled for (which only seems to apply for about 53% of our shares, anyway).
I really think Humanigen is stronger than it has ever been, and I remain super-excited about the recall of our loaned shares.
"(January 8, 2024, 6:35 PM EST) -- Biopharmaceutical company Humanigen Inc. received bankruptcy court approval Monday to access half of a $2 million debtor-in-possession loan to help fund its ongoing drug development operations and its Chapter 11 case."
https://www.google.com/search?q=Humanigen+Gets+Access+To+New+Cash+For+Ch.+11+Process&oq=Humanigen+Gets+Access+To+New+Cash+For+Ch.+11+Process&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRg80gEJNTYxM2owajE1qAIAsAIA&sourceid=chrome&ie=UTF-8#ip=1
This hasn't stopped the Official Committee of Unsecured Creditors of Humanigen from hiring Kilpatrick Townsend & Stockton as co-counsel.
https://www.wsj.com/articles/firm-retention-summary-humanigen-9994dd15?utm_source=dlvr.it&utm_medium=twitter
Seems to me that the DIP Lender, and the Unsecured Creditors, both see some value.
Even more, it makes me wonder what drug development Durrant has keyed-in on at this particular point in time. Is this to support our partners in the PREACH-M trial, or the RATinG trial? It's a very positive sign of Durrant's continuing faith in lenzilumab.
Or, is Durrant's interest in promoting Ifab as an ADC, as shown on slide 3 of our Featured Presentation?
https://ir.humanigen.com/English/events-and-presentations/default.aspx
After all, CytoDyn recently announced that Glioblastoma was being targeted as a treatment candidate with their partners.
Just noting that Intracoastal Capital filed a number of Amended 13G's yesterday, mainly for various biotech holdings, including Baudax. Intercoastal is exercising warrants for over 814K shares of Baudax.
I'm curious to see how this may factor into our interest in Tera-Immune, one week ahead of the Sale Hearing.
https://www.sec.gov/Archives/edgar/data/1646799/000121390024010366/ea192880-13ga1intra_baudax.htm
Time for our own "Extraordinary Measures."
I look at Dale's Appeal, and the Class Action Settlement, and Durrant's move to become both the stalking horse bidder as well as the DIP lender, as legal steps on our journey, which is also causing significant interest in Novavax, which I think will lead to covid market dominance for them in partnership with Humanigen. Time for management now to recall the loaned shares.
Get over it, Yooo. I'm excited abut what is going on here.
eb, I have just sent the following to the Project Manager at AB Data Ltd.
Re: [External]Exclusion from Litigation
Jay Booth
From:
jayatthelake2003@yahoo.com
To:
Ann Cavanaugh
Sat, Feb 3 at 6:15 PM
Dear Ms. Cavanaugh.
Your instruction that I must send a letter by mail, and that I must provide transaction details in Humanigen securities, to be excluded from litigation, impose requirements that I don't feel well enough to comply with. I will simply comply with page 2 of the Notice of Pendency:
"DO NOTHING Get no payment."
I strongly disagree with the Lead Counsel, as I have publicly declared in the following.
cowtown jay
Re: bencozey post# 41218
Tuesday, December 19, 2023 7:38:43 PM
Post#
41220
of 41817 Go
As the ACTIV-5 government-sponsored trial of lenzilumab was announced, I felt that it was nothing more than the commandeering of our successful LIVE-AIR trial results. A simple comparison of the trial designs prove that. Look at the patient inclusion criteria for the two trials.
The government-sponsored ACTIV-5 trial inclusion criteria #6:
"Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) (ordinal score 5, 6, or 7)."
https://clinicaltrials.gov/study/NCT04583969?intr=Lenzilumab&rank=2
The company-sponsored LIVE-AIR trial inclusion criteria:
"SpO2 ≤ 94% on room air and/or require low-flow supplemental oxygen and/or require high-flow oxygen support or NIPPV
Hospitalized, not requiring invasive mechanical ventilation during this hospitalization"
https://clinicaltrials.gov/study/NCT04351152?intr=Lenzilumab&rank=3
The government excluded room air patients in their trial, and included patients on IMV and ECMO. Humanigen did not intend to treat patients that were as seriously ill as the government included in their trial.
And in case you haven't seen just how successful the LIVE-AIR trial results were, here are the peer reviews from Lancet and Thorax on this page.
Humanigen, Inc.
I've been here since 2017. I know the company hoped that ACTIV-5 would corroborate our findings. But including patients in such a late-stage of disease progression in their trial, and excluding the room air patients who did so well in the LIVE-AIR trial, only demonstrates that ACTIV-5 was never going to corroborate the LIVE-AIR trial results.
Lenzilumab is going to be a blockbuster drug (generate over $1B in yearly revenue). Pfizer needs that revenue. But we don't need Pfizer, or any other Big Pharma, to capture this market potential. Durrant has already run 5 blockbuster products through the FDA validation process. And Dale is a specialist in the field of T cell memory function, having been published in his post-doctoral work with the Howard Hughes Medical Institute.
I have shown you the proof of what this management team has done. And I have demonstrated the government's effort to safeguard the revenue of their Big Pharma sponsors. Hopefully, facts will persuade you that the NIH and the FDA are the real culprits here, with the deadly abuse of their discretionary authority."
Thank you,
Jay Booth
The Sale Hearing is scheduled on Feb 14th at 1:30 Eastern. It remains a CH11 case. Humanigen has never been stronger than we are now. All we need is to stay the course on this transformation.
Remember when other bio companies, such as Pfizer, initially reported the efficacy rates of their covid vaccines? Here's an example.
"Published online 2021 Dec 30
Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in a general population has been made possible after the implementation of a nation-wide vaccination program in Israel...
BNT162b2 was found effective for the total population group for infection, hospitalization and mortality, with adjusted VE of 93·0% (CI:92·6–93·4%), 93·4% (CI:91·9–94·7%) and 91·1% (CI:86·5–94·1%) respectively."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717697/
We now know that wasn't true.
The latest iteration reports:
"Newest COVID shots are 54% effective in preventing symptoms, CDC finds
MIKE STOBBE
Thu, February 1, 2024
The latest versions of COVID-19 vaccines were 54% effective at preventing symptomatic infection in adults, according to the first U.S. study to assess how well the shots work."
https://www.yahoo.com/news/newest-covid-shots-54-effective-180123474.html
So in terms of preventing symptomatic infection, vaccines such as Pfizer's represent a coin toss in preventing symptomatic infection. And remember, there is no approved covid treatment authorized by the FDA for the majority of the US population.
After trillions of dollars in damage to the worldwide economies and health care systems, the best we can do is prevent symptomatic infections about half the time, and hope that we won't need a therapeutic treatment, because the FDA hasn't approved one, such as lenz.
I really hope that Humanigen and Novavax will change the covid prevention and treatment paradigm.